Signet Financial Management LLC Has $1.20 Million Stake in Pfizer Inc. (NYSE:PFE)

Signet Financial Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,591 shares of the biopharmaceutical company’s stock after buying an additional 1,730 shares during the period. Signet Financial Management LLC’s holdings in Pfizer were worth $1,197,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Adage Capital Partners GP L.L.C. increased its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new position in Pfizer in the fourth quarter valued at approximately $255,000. Brookstone Capital Management increased its stake in Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after acquiring an additional 212,369 shares during the last quarter. ETF Store Inc. increased its stake in Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 727 shares during the last quarter. Finally, Farmers Trust Co. increased its stake in Pfizer by 2.0% in the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after acquiring an additional 4,410 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.69 on Wednesday. The firm has a market cap of $145.47 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.33. The firm’s fifty day moving average is $27.23 and its 200-day moving average is $28.79.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.